GGrantIndex
← Leaderboards

Brian S J Blagg

Scripps Research Institute

Google Scholar ↗PubMed ↗ORCID ↗
$20,801,107
Attributed
$25,516,982
Total exposure
20
Grants
15
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,516,982 · 20

By mechanism

R01$15,976,027 · 11
U01$4,736,748 · 2
U54$3,954,330 · 1
R21$442,700 · 1
P20$341,429 · 4
F32$65,748 · 1

Top collaborators

Most similar at Scripps Research Institute

Same institution · by research overlap

Others in their field

Top investigators on “Proteins”

Research focus

ProteinsLeadMolecular ChaperonesIn VivoBaseInhibitor/AntagonistToxic EffectClientExhibitsBinding SitesStructureN-TerminalProtein FoldingMalignant NeoplasmsPharmaceutical PreparationsHeat-Shock ResponseAnalogClinical TrialsPreventProtein DegradationIn VitroCollaborationsEvaluationHepatotoxicity

Grant awards (79)

Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma$591,767
R01 · FY2025 · EY · contact PI
Developing isoform-selective Hsp90 inhibitors for monotherapy and enhanced immunotherapy against lethal prostate cancer$551,601
R01 · FY2025 · CA · contact PI
Engineering the Next Generation of Safer Hsp90 Inhibitors$453,814
R01 · FY2025 · CA · contact PI
Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma$617,323
R01 · FY2024 · EY · contact PI
Engineering the Next Generation of Safer Hsp90 Inhibitors$423,618
R01 · FY2024 · CA · contact PI
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.$194,975
R21 · FY2024 · AI
Engineering the Next Generation of Safer Hsp90 Inhibitors$463,293
R01 · FY2023 · CA · contact PI
HSP90 paralog selective small molecules as anti-old-world alpha-viral therapeutic leads.$247,725
R21 · FY2023 · AI
Optimization and Investigation of Cruentaren A analogs$352,952
R01 · FY2021 · CA · contact PI
Hsp90B in Bladder Cancer$351,703
R01 · FY2021 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$387,083
R01 · FY2020 · NS · contact PI
New paradigms for Hsp90 inhibition$354,105
R01 · FY2020 · CA · contact PI
Optimization and Investigation of Cruentaren A analogs$352,952
R01 · FY2020 · CA · contact PI
Hsp90B in Bladder Cancer$351,703
R01 · FY2020 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$387,083
R01 · FY2019 · NS · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$353,294
R01 · FY2019 · CA · contact PI
New paradigms for Hsp90 inhibition$343,480
R01 · FY2019 · CA · contact PI
Optimization and Investigation of Cruentaren A analogs$342,525
R01 · FY2019 · CA · contact PI
Hsp90B in Bladder Cancer$341,150
R01 · FY2019 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$384,583
R01 · FY2018 · NS · contact PI
Hsp90B in Bladder Cancer$365,328
R01 · FY2018 · CA · contact PI
New paradigms for Hsp90 inhibition$354,105
R01 · FY2018 · CA · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$443,918
R01 · FY2017 · CA · contact PI
Grp94-selective inhibitors to treat heredity glaucoma$416,063
R01 · FY2017 · EY
New paradigms for Hsp90 inhibition$366,572
R01 · FY2017 · CA · contact PI
Optimization and Investigation of Cruentaren A analogs$357,067
R01 · FY2017 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$352,351
R01 · FY2017 · NS · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$84,000
R01 · FY2017 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$32,232
R01 · FY2017 · NS · contact PI
Grp94-selective inhibitors to treat heredity glaucoma$418,426
R01 · FY2016 · EY
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$359,918
R01 · FY2016 · CA · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$240,455
R01 · FY2016 · CA · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$77,751
R01 · FY2016 · CA · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$71,899
R01 · FY2016 · CA · contact PI
Grp94-selective inhibitors to treat heredity glaucoma$412,324
R01 · FY2015 · EY
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$372,418
R01 · FY2015 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$317,274
R01 · FY2015 · NS · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$312,346
R01 · FY2015 · CA · contact PI
Grp94-selective inhibitors to treat heredity glaucoma$435,379
R01 · FY2014 · EY
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$326,800
U01 · FY2014 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$314,419
R01 · FY2014 · NS · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$302,858
R01 · FY2014 · CA · contact PI
HSP90 Inhibitors$218,972
U01 · FY2014 · CA · contact PI
Center Based Research Project$397,722
U54 · FY2013 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$323,039
U01 · FY2013 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$306,763
R01 · FY2013 · NS · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$293,016
R01 · FY2013 · CA · contact PI
HSP90 Inhibitors$220,737
U01 · FY2013 · CA · contact PI
Center Based Research Project$630,554
U54 · FY2012 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$350,515
U01 · FY2012 · CA · contact PI
Development of Hsp90 inhibitors for the treatment of cancer$322,961
R01 · FY2012 · CA · contact PI
Chaperone therapeutics for the treatment of DPN$318,158
R01 · FY2012 · NS · contact PI
HSP90 Inhibitors$239,523
U01 · FY2012 · CA · contact PI
Center Based Research Project$763,443
U54 · FY2011 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$369,318
U01 · FY2011 · CA · contact PI
HSP90 Inhibitors$244,314
U01 · FY2011 · CA · contact PI
Center Based Research Project$694,304
U54 · FY2010 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$355,744
U01 · FY2010 · CA · contact PI
Hsp90 Inhibitors$246,281
U01 · FY2010 · CA · contact PI
Center Based Research Project$860,858
U54 · FY2009 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors$352,665
U01 · FY2009 · CA · contact PI
Hsp90 Inhibitors$246,345
U01 · FY2009 · CA · contact PI
Center Based Research Project$607,449
U54 · FY2008 · HG · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`$248,188
U01 · FY2008 · CA · contact PI
Hsp90 Inhibitors$246,408
U01 · FY2008 · CA · contact PI
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS$26,054
P20 · FY2008 · RR · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`$248,188
U01 · FY2007 · CA · contact PI
Hsp90 Inhibitors$246,469
U01 · FY2007 · CA · contact PI
HTS Assays for Hsp90 Inhibitors$207,111
R01 · FY2007 · CA · contact PI
Development and Evaluation of Purine and Coumarin Based Hsp90 Inhibitors`$255,600
R01 · FY2006 · CA · contact PI
Hsp90 Inhibitors$253,242
U01 · FY2006 · CA · contact PI
HTS Assays for Hsp90 Inhibitors$214,047
R01 · FY2006 · CA · contact PI
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS & PROTEINS$27,228
P20 · FY2006 · RR · contact PI
HTS Assays for Hsp90 Inhibitors$247,239
R01 · FY2005 · CA
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS &PROTEINS$164,954
P20 · FY2005 · RR
COBRE: U KS: P1: ID OF HSP90 COCHAPERONES, IMMUNOPHILINS &PROTEINS$123,193
P20 · FY2004 · RR
Identification of Hsp90 cochaperones, Immunophillins, &client proteins$0
P20 · FY2002 · RR
ASYMMETRIC TOTAL SYNTHESIS OF ROSEOPHILIN$34,832
F32 · FY2001 · CA
ASYMMETRIC TOTAL SYNTHESIS OF ROSEOPHILIN$30,916
F32 · FY2000 · CA